Publications by authors named "Maud Barbery"
Article Synopsis
- Immunotherapies have shown limited success in treating nodal peripheral T-cell lymphomas (PTCLs) due to a poor understanding of their immune responses.
- Researchers conducted detailed analyses of the immune tumor microenvironment (TME) in various PTCL samples, revealing a higher presence of regulatory T cells and exhausted CD8+ T cells.
- The study found that high levels of CD39 expression on T cells are associated with worse patient outcomes, suggesting it as a potential new prognostic factor and target for treatment.
Purpose: Xevinapant is an orally available inhibitor of apoptosis proteins (IAP) inhibitor. Preclinical data suggest that IAP antagonism may synergize with immune checkpoint blockers by modulating the NFκB pathway in immune cells.
Patients And Methods: Adult patients with non-high microsatellite instability advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer were enrolled in this phase Ib/II study and received pembrolizumab 200 mg every 3 weeks intravenously, and ascending doses of oral xevinapant (100, 150, and 200 mg daily for 14 days on/7 days off).
The membrane-anchored Src tyrosine kinase is involved in numerous pathways and its deregulation is involved in human cancer. Our knowledge on Src regulation relies on crystallography, which revealed intramolecular interactions to control active Src conformations. However, Src contains a N-terminal intrinsically disordered unique domain (UD) whose function remains unclear.
View Article and Find Full Text PDF